Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab

Autor: Harry K. Genant, Christopher Recknor, Richard Eastell, Jose R. Zanchetta, Jacques P. Brown, David L. Kendler, Thomas Fuerst, Tony M. Keaveny, Stefan Goemaere, Michael R. McClung, Hoi-Shen Radcliffe, Cesar Libanati, Maria Luisa Brandi, David L. Kopperdahl, Klaus Engelke
Rok vydání: 2013
Předmět:
OVARIECTOMIZED CYNOMOLGUS MONKEYS
Aging
PROXIMAL FEMUR
Endocrinology
Diabetes and Metabolism

Osteoporosis
OSTEOPOROSIS
Medical and Health Sciences
Engineering
Absorptiometry
Photon

Monoclonal
Medicine and Health Sciences
Orthopedics and Sports Medicine
Quantitative computed tomography
Tomography
Humanized
Osteoporosis
Postmenopausal

Hip fracture
medicine.diagnostic_test
Biological Sciences
Anatomy & Morphology
Photon
X-Ray Computed
Biomechanical Phenomena
Postmenopause
Trabecular bone
medicine.anatomical_structure
Denosumab
6.1 Pharmaceuticals
HIP STRENGTH
Postmenopausal
Female
BONE-MINERAL DENSITY
medicine.drug
SPINE STRENGTH
musculoskeletal diseases
medicine.medical_specialty
Clinical Trials and Supportive Activities
Finite Element Analysis
Antibodies
Monoclonal
Humanized

Placebo
Antibodies
OSTEOCLAST DIFFERENTIATION
Clinical Research
medicine
Humans
Absorptiometry
Aged
DENOSUMAB
Hip
Postmenopausal women
business.industry
QUANTITATIVE COMPUTED-TOMOGRAPHY
TRABECULAR BONE
Evaluation of treatments and therapeutic interventions
HIP FRACTURE
IN-VITRO
Original Articles
HUMAN RANKL ANTIBODY
medicine.disease
Spine
Surgery
Musculoskeletal
Injury (total) Accidents/Adverse Effects
Cortical bone
FINITE-ELEMENT-ANALYSIS
Tomography
X-Ray Computed

business
Zdroj: Journal of Bone and Mineral Research
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, vol 29, iss 1
JOURNAL OF BONE AND MINERAL RESEARCH
ISSN: 1523-4681
0884-0431
Popis: In the randomized, placebo-controlled FREEDOM study of women aged 60 to 90 years with postmenopausal osteoporosis, treatment with denosumab once every 6 months for 36 months significantly reduced hip and new vertebral fracture risk by 40% and 68%, respectively. To gain further insight into this efficacy, we performed a nonlinear finite element analysis (FEA) of hip and spine quantitative computed tomography (QCT) scans to estimate hip and spine strength in a subset of FREEDOM subjects (n = 48 placebo; n = 51 denosumab) at baseline, 12, 24, and 36 months. We found that, compared with baseline, the finite element estimates of hip strength increased from 12 months (5.3%; p
Databáze: OpenAIRE